(1.02%) 5 099.96 points
(0.40%) 38 240 points
(2.03%) 15 928 points
(-0.92%) $83.08
(-1.16%) $1.619
(-0.35%) $2 339.00
(-0.05%) $27.52
(0.53%) $927.00
(-0.17%) $0.933
(-0.17%) $11.01
(-0.25%) $0.798
(0.00%) $92.17
Live Chart Being Loaded With Signals
GT Biopharma, Inc., a clinical stage biopharmaceutical company, focuses on the development and commercialization of immuno-oncology products based on its proprietary Tri-specific Killer Engager (TriKE) fusion protein immune cell engager technology platform...
Stats | |
---|---|
本日の出来高 | 10 324.00 |
平均出来高 | 13 556.00 |
時価総額 | 4.62M |
EPS | $-2.19 ( 2024-04-04 ) |
次の収益日 | ( $-2.70 ) 2024-05-12 |
Last Dividend | $0 ( N/A ) |
Next Dividend | $0 ( N/A ) |
P/E | -0.600 |
ATR14 | $0.103 (3.08%) |
Date | Person | Action | Amount | type |
---|---|---|---|---|
2023-08-11 | Breen Michael Martin | Buy | 200 000 | Common Stock |
2023-08-11 | Ohri Manu | Buy | 200 000 | Common Stock |
2023-08-11 | Ohri Manu | Buy | 200 000 | Common Stock |
2023-08-11 | Ohri Manu | Sell | 200 000 | Common Stock |
2023-06-16 | Casamento Charles J | Buy | 500 000 | Option to purchase Common Stock |
INSIDER POWER |
---|
83.37 |
Last 90 transactions |
Buy: 52 855 774 | Sell: 22 501 893 |
GT Biopharma, Inc. 相関
10 最も正の相関 |
---|
10 最も負の相関 |
---|
知っていましたか?
相関は、2つの変数間の関係を説明する統計的指標です。相関係数は-1から1までの値を取り、-1は完全な負の相関(1つの変数が増加すると、もう一方は減少する)、1は完全な正の相関(1つの変数が増加すると、もう一方も増加する)、0は相関がないことを示します(変数間に関係がない)。
相関は、株式だけでなく、どの2つの変数間の関係にも適用できます。これは、金融、経済学、心理学などの分野で一般的に使用されています。
GT Biopharma, Inc. 財務諸表
Annual | 2023 |
収益: | $0 |
総利益: | $0 (0.00 %) |
EPS: | $-5.64 |
FY | 2023 |
収益: | $0 |
総利益: | $0 (0.00 %) |
EPS: | $-5.64 |
FY | 2022 |
収益: | $0 |
総利益: | $0 (0.00 %) |
EPS: | $-19.30 |
FY | 2021 |
収益: | $0.00 |
総利益: | $0.00 (0.00 %) |
EPS: | $-2.06 |
Financial Reports:
No articles found.
GT Biopharma, Inc.
GT Biopharma, Inc., a clinical stage biopharmaceutical company, focuses on the development and commercialization of immuno-oncology products based on its proprietary Tri-specific Killer Engager (TriKE) fusion protein immune cell engager technology platform. It develops GTB-3550, a single-chain tri-specific recombinant fusion protein conjugate that is in Phase I/II clinical trial for the treatment of myelodysplastic syndromes, refractory/relapsed acute myeloid leukemia or advanced systemic mastocytosis, and CD33+ malignancies. The company is developing GTB-3650, which is in preclinical studies that target CD33 on the surface of myeloid leukemias; and GTB-5550 that is in preclinical studies for treating patients with B7-H3 positive solid tumors. GT Biopharma, Inc. has a co-development partnership agreement with Altor BioScience Corporation for the clinical development of a 161533 TriKE fusion protein for cancer therapies; and a license agreement with the Regents of the University of Minnesota to develop and commercialize cancer therapies using TriKE technology. The company was formerly known as OXIS International, Inc. and changed its name to GT Biopharma, Inc. in July 2017. GT Biopharma, Inc. was incorporated in 1965 and is based in Brisbane, California.
について ライブシグナル
このページで提示されるライブシグナルは、NA を買う時や売る時を判断するのに役立ちます。シグナルには1分以上の遅延があります。市場シグナルには誤りやミスの可能性があるため、ライブ取引シグナルは決定的ではなく、getagraph.comはこれらのシグナルに基づく任意の行動について責任を負いません。詳細については、利用規約で説明されているように、技術分析指標に基づいています。